Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

TY - JOUR

T1 - Phase i and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

AU - Giles, F. J.

AU - Vey, N.

AU - Rizzieri, D.

AU - Ravandi, F.

AU - Prebet, T.

AU - Borthakur, G.

AU - Jacobsen, T. F.

AU - Hagen, S.

AU - Nilsson, B.

AU - O'Brien, S.

N1 - Funding Information: This study was supported by the Canadian Institutes of Health Research (CIHR) and the Leukemia and Lymphoma Society of Canada (to DS) and a QEII-SST graduate scholarship from the University of Toronto (to ST). Funding Information: FJ Giles, N Vey, D Rizzieri and S O’Brien have received research funding from Clavis Pharma. TF Jacobsen, S Hagen and B Nilsson are/were Clavis Pharma employees.

PY - 2012/7

Y1 - 2012/7

UR - http://www.scopus.com/inward/record.url?scp=84863779790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863779790&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.1

DO - 10.1038/leu.2012.1

M3 - Letter

C2 - 22222600

AN - SCOPUS:84863779790

SN - 0887-6924

VL - 26

SP - 1686

EP - 1689

JO - Leukemia

JF - Leukemia

IS - 7

ER -